Niagen Bioscience (NAGE) Gross Margin (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Gross Margin of 63.47% for Q1 2026, up 5.0% year-over-year from 60.45% in Q1 2025, and down 1.05% quarter-over-quarter from 64.14% in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Gross Margin (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Gross Margin for 17 consecutive years, with 63.47% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin rose 5.0% year-over-year to 63.47%; the TTM figure through Mar 2026 stood at 64.28% (up 177.0% YoY), while the FY2025 annual figure was 64.28%, up 244.0% from the prior year.
- Gross Margin declined to 63.47% in Q1 2026 per NAGE's latest filing, from 64.14% in the prior quarter.
- Across five years, Gross Margin topped out at 65.0% in Q2 2025 and bottomed at 57.23% in Q4 2022.
- Historically, Gross Margin has averaged 61.69% across 5 years, with a median of 61.04% in 2023.
- Annual changes were most pronounced in 2022 — Gross Margin sank 397 bps — and 2025, when it surged 478 bps.
- Niagen Bioscience's Gross Margin stood at 57.23% in 2022, then grew by 7 bps to 61.04% in 2023, then rose by 2 bps to 62.48% in 2024, then gained by 3 bps to 64.14% in 2025, then fell by 1 bps to 63.47% in 2026.
- Business Quant data shows NAGE's Gross Margin at 63.47% in Q1 2026, 64.14% in Q4 2025, and 64.52% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | 64.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64.84% |
| Mar 31, 2026 | 63.47% |
| Dec 31, 2025 | 64.14% |
| Sep 30, 2025 | 64.52% |
| Jun 30, 2025 | 65.00% |
| Mar 31, 2025 | 63.42% |
| Dec 31, 2024 | 62.48% |
| Sep 30, 2024 | 63.49% |
| Jun 30, 2024 | 60.22% |
| Mar 31, 2024 | 60.74% |
| Dec 31, 2023 | 61.04% |
| Sep 30, 2023 | 61.40% |
| Jun 30, 2023 | 60.80% |
| Mar 31, 2023 | 59.93% |
| Dec 31, 2022 | 57.23% |
| Sep 30, 2022 | 59.82% |
| Jun 30, 2022 | 60.02% |
| Mar 31, 2022 | 61.02% |
| Dec 31, 2021 | 61.20% |
| Sep 30, 2021 | 61.12% |